Introduction
There continues to be a steady increase in the incidence of significant polyps and early colorectal cancer (SPECC), largely driven by the implementation of bowel cancer screening programmes (BCSP) worldwide. Whilst there are substantial oncological benefits of detecting earlystage colorectal cancer and removing precancerous adenomatous polyps [1, 2] , new management dilemmas have arisen regarding the optimal treatment for complex polyps detected at colonoscopy, the majority of which are benign. Endoscopic resection has been reported to be safe, efficient [3] and cost effective [4] compared with surgical excision, which should ideally be reserved for patients in whom safe and complete polypectomy is not achievable, or for polyps deemed to be clinically malignant irrespective of negative histology at biopsy [5] .
Despite these recommendations, significant variation exists in the treatment of SPECC, particularly in relation to the utilization of resectional surgery. In the English BCSP, a fivefold variation in the use of surgery has been observed, between screening units, for the treatment of complex colorectal polyps [6] . More recently, population-level data from North America suggest an increase in the rate of surgical resection for patients with benign colorectal polyps [7] . The underlying reasons for these disparities are complex and multifactorial, but often relate to suboptimal assessment and characterization of lesions at index colonoscopy, the lack of standardized treatment algorithms, deficiencies in interdisciplinary co-operation and the challenges of accurate histopathological evaluation of polyps. This paper discusses some of these aspects in greater detail, with the aim that a wider awareness of these pitfalls may help to stratify treatment decisions appropriately and minimize the potential for under-or overtreatment in this patient group.
Endoscopic polyp assessment
A comprehensive assessment of polyp size, visual morphology and location within the colorectum, ideally recorded by photographic or video documentation, is crucial to the subsequent management of a complex lesion. Larger polyp size has consistently been shown to be associated with the risk of invasive malignancy [8] , complexity of successful endoscopic resection and the need for surgical resection [5] , and accurate measurement of polyp size is therefore strongly recommended. However, polyp size measurement in vivo remains problematic and is highly unreliable by optical judgment alone [9] , with a bias towards overestimating the actual size [10] . The meticulous assessment of polyp morphology and surface characteristics is equally important for determining the malignant potential of a lesion. However, with several classification systems either already in use or being introduced [11] , consistent and reproducible reporting remains a major issue. In the UK, the Paris classification is recommended for evaluating polyp morphology [5] , but a study of interobserver reproducibility found only moderate agreement, even amongst international experts, with application of the Paris classification in routine clinical practice being questioned [12] . Finally, the reliance on superficial biopsies to diagnose malignancy in a polyp is also contentious and may lead to suboptimal treatment if endoscopic resection is recommended. Multiple studies have shown that even with benign superficial biopsies, the risk of finding an unexpected cancer in the post-treatment specimen is approximately 10%, highlighting the importance of complementary assessment tools to aid decision making [13] .
Thus, the descriptive interpretations of colorectal polyp assessment are subject to variation and have been shown to be discordant between practitioners. To this effect, the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG) have jointly developed a highly recommended minimum dataset tool for the standardized assessment of SPECC lesions [14] with the hope that treatment variations may be minimized.
Multidisciplinary team input
Despite the evolution of advanced polypectomy techniques, such as endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD), the numbers of patients undergoing resectional surgery for significant, but benign, colorectal polyps has remained relatively static [15] . Population-level data suggest that the variation in referral rates for surgical resection is associated with individual endoscopists and their specialty [16] , with surgeons more likely to recommend surgical resection as a treatment modality [17] . Thus, specialist 'tribalism' continues to dominate the management of SPECC lesions and may be alleviated by a multidisciplinary referral process which facilitates appropriate allocation of treatment based on clinical need. There is increasing evidence that surgical resection is unwarranted for many polyps which are initially considered, at diagnosis, as unsuitable for endoscopic resection, provided patients are referred to an appropriate therapeutic endoscopist [18, 19] . To optimize this process, a dedicated system which enables multidisciplinary dialogue is highly desirable, and in the UK, several informal regional referral networks and significant polyp multidisciplinary teams (MDTs) have developed and are evolving [20] . The role and importance of SPECC-MDTs in improving patient outcomes is discussed elsewhere in this supplement.
Quality assurance, audit and training
A robust quality-assurance and audit process is essential for improving clinical services. A prime example of this is the national BCSP, which mandates colonoscopists to deliver a high standard of key performance indicators to achieve and maintain accreditation [21] . The effect of this process is evolution of the BCSP into a high-quality diagnostic service, with substantial improvements in several performance targets, including caecal intubation rates, adenoma detection and removal rates, colonoscopy withdrawal time and low adverse events [22] . Recent evidence suggests that these benefits may also have become transposed to the therapeutic setting, demonstrated as improvements related to the treatment of significant colorectal polyps. A UK multicentre study reported that significant polyps diagnosed within the BCSP were both more likely to undergo primary endoscopic resection at the index colonoscopy and 2.6-fold less likely to be treated by surgical resection, compared with polyps detected at non-screening colonoscopy [13] . These disparities may, in part, result from the variable accreditation standards between the nonscreening and BCSP systems, and there is ongoing debate regarding whether such a system may lead to the evolution of a two-tier clinical service [23, 24] . A universal set of quality assurance criteria for both screening and symptomatic patient groups may help to minimize variable assessment and treatment outcomes for patients with SPECC lesions, irrespective of the referral source.
Pathological assessment
Accurate histopathological evaluation of a resected SPECC lesion is important for distinguishing benign from malignant polyps, risk stratification and guiding post-resection treatment and surveillance strategy. This is perhaps most relevant in the context of an incidental polyp cancer found in a post-polypectomy specimen, as patients often face the prospect of additional major resectional surgery when, in many cases, there may be no residual malignant disease. Reports from multiple UK studies suggest that this may be the situation in up to 75% of cases [13, 25, 26] , with some patients having significant morbidity following bowel resection. Whilst nonoperative surveillance is an attractive option in these patients, the difficulties of accurate histopathological prognostication in polyp cancers makes informed decision-making problematic, leading to variations in surgical treatment.
The two key components of pathological evaluation in a polyp cancer are (i) margin clearance and (ii) the presence of any adverse prognostic features which predict lymph node involvement. Unfortunately, there is no consensus on what defines a clear 'tumour-free' margin [27] , and the current threshold of ≤1 mm to indicate margin involvement in polyp cancers has been questioned [26] . Assessment of margin involvement is further compounded by diathermy artefact and the challenges of evaluating degraded or piecemeal specimens. This also affects the accurate assessment of other adverse prognostic features, such as the Haggitt level or Kikuchi stage; the latter requires the muscularis propria to be present in sessile polyps but it is frequently absent from mucosal resections [27] . Finally, there is considerable interobserver variation in pathological reporting of specimens [28] , adding to the diagnostic uncertainty and variability in treatment.
Conclusion
A substantial proportion of the variation in treating SPECC lesions results from decisions made in the preintervention phase, many of which can be optimized by careful lesion assessment and involvement of a MDT. The onus is on practitioners to approach these 'highvalue' lesions meticulously, so that malignancy can be either confirmed or ruled out with reasonable certainty. Attention to detail and knowledge of SPECC lesions, their assessment and multidisciplinary management allow optimal definitive treatment of the patient using the least morbid technique, by the most appropriately skilled specialist.
